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ABSTRACT
A strong link between bronchiolitis and asthma has been
indicated. Bronchiolitis that occurs in infants is manifested
physiologically by a widespread narrowing of the air pas-
sages and, clinically, by asthma-like symptoms.The major
cause of bronchiolitis is respiratory syncytial virus infec-
tion. While the precise pathophysiologic sequences of
infection are incomplete, many observations have sug-
gested that there is an infiltration of eosinophils in the
airways. Current studies have shown that the respiratory
syncytial virus penetrates the pulmonary defenses and ini-
tiates immunologic responses. The histamine and
leukotriene mediators that are released produce an
inflammatory reaction and the chemotactic factors bring
eosinophils to the site of the reaction. Degranulation of
eosinophils can release eosinophil cationic protein into
the airways. Our finding that chemoattractants for
eosinophils, interleukin-8 and RANTES (regulated upon
activation, normal T cell expressed and presumably
secreted) were detected in nasopharyngeal aspirates of
infants with bronchiolitis suggests that such chemokines
from epithelial cells may induce an eosinophil infiltration
in the airway. Similar allergic inflammatory changes have
been observed in asthma and in epithelial cells infected
with respiratory viruses. Future investigation of the mecha-
nism by which bronchiolitis can induce asthma will
provide benefits in the treatment and prevention of
asthma in sensitive individuals.
Key words: asthma, bronchiolitis, chemokine,
eosinophil cationic protein, RANTES (regulated upon
activation, normal T cell expressed and presumably
secreted), respiratory syncytial virus.
INTRODUCTION
Today, in industrialized countries, asthma is a leading
chronic childhood disease.1 According to the Dutch
hypothesis of the natural history of chronic airway
disease, childhood asthma is generally atopic and devel-
ops following allergen exposure, but additional factors,
such as viral respiratory infections, are usually required
for the clinical features of asthma to develop.2
Epidemiologic or cohort studies have also suggested that
viral respiratory infections are the most common stimuli
that evoke acute exacerbations of asthma.3,4 Recent
studies have provided new findings on the mechanism of
respiratory syncytial virus (RSV) infection in association
with asthma. Therefore, this is a critical issue in the pre-
vention of the development of asthma in adulthood.
In the present paper we review RSV infection and the
wheezing illness of bronchiolitis in early infancy, as well as
asthma.
VIRAL RESPIRATORY INFECTION AND WHEEZING
IN CHILDHOOD
Acute respiratory infections are the most common child-
hood illnesses. Over 90% of these infections are caused
by more than 200 viruses. The peak frequency of acute
lower respiratory tract infection is approximately 20–30
episodes/1000 children per year in infants and gradually
declines to five episodes/1000 children per year by 9
years of age, where it remains throughout adolescence
(Fig. 1).5
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Many studies have indicated that there is a strong link
between bronchiolitis in infancy and asthmatic symptoms
in later childhood.6–8 In the first year of life, 30% of all
infants have at least one episode of wheezing due to a
viral respiratory infection. Of these, one-third of infants
still wheeze by 6 years of age and manifest childhood
asthma.9 Some studies have demonstrated that children
who started to wheeze in early life and who continued to
wheeze at 6 years of age were more likely to have
mothers with a history of asthma, elevated serum IgE
levels and to have normal lung function in the first year of
life and diminished values for maximal expiratory flow at
functional residual capacity ( V˙max FRC) than those who
had never wheezed.10 Respiratory syncytial virus is the
major cause of acute lower respiratory tract infection,
particularly in infancy, and is responsible for approxi-
mately 80% of bronchiolitis, 30% of pneumonia, 15% of
bronchitis and 12% of croup cases.5
RESPIRATORY SYNCYTIAL VIRUS INFECTION
General virology of RSV
Respiratory syncytial virus was first isolated in 1956.11 It
belongs to the paramyxovirus family and is medium sized
(120–300 nm), with a lipid envelope surrounding RNA.
On the surface of the lipid envelope, the fusion (F),
attachment (G) and unknown function (SH) glycoproteins
are expressed. There are also the M1 (first matrix) and
M2 (second matrix or 22 kDa) proteins in the matrix and
the nucleoprotein (N), phosphoprotein (P) and large
protein (L) in the nucleocapsid (Table 1).12
The virus attaches to host cells via a G-protein and
penetrates via the district F protein. These structural pro-
teins are important viral antigenic determinants and
initiate immunologic responses. Respiratory syncytial
virus has two serologic subgroups: (i) the A (long-strain
prototype); and (ii) the B (18537 strain prototype).
Clinical differences between the two serotypes have been
elusive, although some studies indicate that B strains
cause less severe disease.
Transmission of RSV
The major mode of transmission of RSV appears to be 
by larger droplets, like rhinovirus, rather than by small-
particle aerosols, as for influenza virus infections.
Transmission requires either close contact with infected
individuals or contamination of the hands and subse-
quent contact between fingers and nasal or conjunctival
mucus.13 These transmission patterns may translate into a
slower spread of the disease and not be pandemic.
Respiratory syncytial virus replication is initially con-
fined to the nasopharynx, with an incubation period of
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Fig. 1 (a) Total number of
episodes of acute lower respira-
tory infection/1000 children per
year compared with age and
the number of episodes of (b)
acute laryngotracheobronchitis,
(c) bronchitis, (d) acute viral
bronchiolitis and (e) pneumonia.
Reproduced with permission
from Phelan et al.5
4–6 days. Infected cells spread from direct mucosal cell-
to-cell contact and form a syncytium. Clinical symptoms
of lower respiratory tract infection manifest 1–3 days after
the onset of nasopharyngeal infection.
Epidemiology of RSV infection
Approximately 70% of children have received an initial
RSV infection by 12 months of age. This virus usually
causes lower respiratory tract disease in infancy. The
peak incidence of bronchiolitis is between 1 and 6
months of age, while pneumonia occurs throughout the
first year of life.5 Overall, 1–2% of RSV infections result in
hospitalization for bronchiolitis and pneumonia. The
mortality rate for RSV is less than 1% of all hospitalized
patients;14 however, it rises in high-risk groups15 such as
premature infants and infants with congenital heart
disease,16 chronic lung disease17 or immunosuppressive
diseases.18 After the age of 3–4 years, RSV usually causes
upper respiratory tract infections. Despite long-lasting
serum antibodies, reinfection is common.19,20
Respiratory syncytial virus and bronchiolitis
The diagnosis of bronchiolitis is made if an infant
acquires asthma-like symptoms and it is known that RSV
is endemic.21 Bronchiolitis occurs only in infancy. Because
the first infection in infancy cannot exhibit a sufficient
immune defense for RSV,22 infected viruses may easily
spread to the lower respiratory tract. In addition, the
small conducting airways in infants are more easily
obstructed by inflammation than in adults.23 Moreover, a
large area of injured airway epithelial cells may create
prolonged hypersensitivity in the airway. Bronchiolitis and
asthma are very similar clinical illnesses, with a few differ-
ences (Table 2).
Bronchiolitis is characterized histologically by a peri-
bronchiolar mononuclear infiltration with edema of the
walls.24 A recent autopsy study of infants who died of RSV
infection has confirmed the shedding of virus-infected
epithelial cells into the bronchial lumen.25
Treatment and prevention of bronchiolitis
Infants with respiratory distress caused by bronchiolitis
should be hospitalized, but generally only supportive
treatment is given. b -Adrenoceptor agonists and cortico-
steroids are used for the treatment of bronchiolitis
empirically.21 However, responses to bronchodilators are
unpredictable: some infants show prompt improvement
on inhalation, but others resist such treatment and gain no
benefit.26 A number of prospective controlled trials to
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Table 1 Major proteins of respiratory syncytial virus
Reproduced with permission from Openshaw.63
Table 2 Differences between childhood bronchiolitis and
asthma
RSV, respiratory syncytial virus; CLD, chronic lung disease; CHD,
congenital heart disease.
Protein kDa Glycosylation Viability Function
Surface proteins
G-protein 84 63%, O-linked +++ Attachment
F protein 68 5%, N-linked ++ Fusion
SH ~ 20 50–70% + Unknown
Matrix proteins
M1 26 + Membrane stability?
M2(22 kDa) 22 (+) Unknown
Nucleocapsid
Nucleoprotein 42 (+) Structural
Phosphoprotein 34 (+) Polymerase component?
Large protein 250 (?) RNA polymerase
Bronchiolitis Asthma
Cause Infection (RSV) Allergy
Course Acute Chronic
Age Infant (< 6 months) All
Sex Male > female Male > female
Season Winter Autumn, spring
Treatment Ribavirin® Steroid, 
b -adrenoceptor 
agonists
Risk Immature infant, Atopy
CLD, CHD,
immune deficiency
evaluate corticosteroids in the treatment of bronchiolitis
have been inconclusive.27 The recent National Institutes 
of Health (NIH) Guidelines for the Diagnosis and
Management of Asthma recommended that inhalation of
b -adrenoceptor agonists and corticosteroids was
attempted for wheezy infants, because the symptoms of
bronchiolitis and asthma cannot be differentiated.28
Ribavirin® (Viazole, ICN Pharmaceuticals, Coscimes,
USA) aerosol, a synthetic nucleoside that acts by limiting
viral replication, is currently recommended for use in
high-risk patients.29
Currently, experimental therapies are available or
under investigation for the prevention of RSV infection by
active immunization. In the early 1960s, a formalin-
inactivated RSV (FI-RSV) vaccine used in trials showed
that recipients of the vaccine suffered from more severe
bronchiolitis following RSV infection than control
infants.30 Despite current efforts to develop subunit vac-
cines, such as F protein or live attenuated vaccines, none
of these has succeeded to date.31 Passive immunization in
high-risk groups has also been tried. Clinical trials using
standard intravenous immunoglobulin failed to demon-
strate a reduction in the hospitalization rate.32 In the late
1980s, infants who received RSV-enriched immunoglob-
ulin achieved sufficiently high neutralizing antibody levels
to result in a reduction of the hospitalization rate.33
However, subgroup infants with congenital heart disease
failed to show a reduction in the severity of RSV infection.
Immunoglobulin enriched with RSV was licensed by the
Food and Drug Administration (USA) and has been avail-
able in the US since 1996. There was a recent trial of
monoclonal antibodies for prophylaxis against RSV infec-
tion because of the possibility of intramuscular injection
due to small amounts required.34
AIRWAY INFLAMMATION IN ASTHMA
Asthma has been defined by airway hypersensitivity and
reversible airway flow limitation for an extended period.35
In addition to these symptoms, asthma is defined in the
first NIH Guidelines issued in1991 as chronic airway
inflammation characterized by an influx of mast cells,
lymphocytes and eosinophils.36 The most important of
these may be the influx of eosinophils.
The presence of peripheral eosinophilia in asthmatic
patients is well known. It has also been recognized that a
number of eosinophils are frequently found in and
around the bronchi of patients who have died of
asthma.37 The immunostaining of bronchial tissue from
such patients has revealed the existence of a major basic
protein, which is one of the granule proteins in the
eosinophil, deposited in the airway.38 Eosinophilia in the
airway indicates the allergic inflammation of asthma, in
contrast with the neutrophilia observed in common acute
inflammation.39
According to a recent immunologic concept, inflam-
mation is modulated by T helper (Th) lymphocytes, which
are classified into Th1 and Th2 types based on their
pattern of cytokine production. The Th1 cells secrete
interferon (IFN)-g , interleukin (IL)-2 and tumor necrosis
factor-b , whereas Th2 cells secrete IL-4, IL-5, IL-6, IL-10
and IL-13. The Th1 cells enhance cellular or infectious
immune responses, while Th2 cells enhance humoral or
allergic immune responses, such as asthma.40 There is a
counterinhibitory link between Th1 and Th2 lymphocytes:
Th2 cells produce IL-10, which inhibits the growth and
function of Th1 cells, while Th1 cells produce IFN-g ,
which inhibits Th2 cell activity (Fig. 2).41
The hypothesis based on the Th1 and Th2 theory is
able to explain that when allergens such as house dust
mites are inhaled, they will interact with airway epithelial
cells, Th2 cells and intraepithelial mast cells.This results
in the release of chemokines, such as RANTES (regulated
upon activation, normal T cell expressed and presumably
secreted), or cytokines, such as IL-4 and IL-5, which
promote selective eosinophil migration. Eosinophils
release granule proteins, which cause epithelial damage,
and lipid-derived mediators (e.g. leukotriene), which
cause mucus hypersecretion and bronchoconstriction in
addition to further supporting eosinophil recruitment.42
EFFECTS OF VIRAL INFECTION IN AIRWAY
INFLAMMATION
It has been shown that the virus affects airway hypersensi-
tivity and air flow limitation, as a result of epithelial
disruptions, cholinergic and adrenergic nerve dysfunc-
tions and inactivations of tachykinins such as substance P.
In addition to these, it has recently been noted that viral
respiratory infections can associate with eosinophil infil-
tration in the airways (Fig. 3).43
T cells
Some studies have shown increased levels of IFN-g , IL-2
and Th1 cytokines in peripheral blood mononuclear cells
infected with respiratory viruses.44 However, results from
other studies have shown that viral infections can induce
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both Th1- and Th2-type cytokine responses.45 Viral infec-
tions are known to activate CD4+ T cells and produce a
Th1-type immune response, however it has not been
determined how viral infections can cause an increase in
Th2-type cytokines. Recent studies have demonstrated
that CD8+ T cells produce both IFN-g and IL-10 mRNA,
with lower levels of IL-2, IL-4 and IL-5 in bronchoalveolar
lavage fluid of virus-infected mice.46,47 These results
suggest that CD8+ T cells play a critical role in regulating
Th2-driven eosinophilia.
Epithelium
Current studies have demonstrated that many kinds of
cytokines and chemokines are generated by airway
epithelial cells infected with respiratory viruses. Up-
regulation of IL-1 b , IL-6, IL-8, IL-11, IFN- g , tumor
necrosis factor (TNF)- a and granulocyte–macrophage
colony stimulating factor (GM-CSF) expression has
been reported in epithelial cells infected with viruses
such as RSV.48,49 More recent studies have shown that
regulated upon activation, normal T cell expressed and
presumably secreted (RANTES) is produced from RSV-
infected epithelial cells.50,51 A CC chemokine, RANTES
is an effective and selective chemoattractant for
eosinophils.52 Airway epithelial cells infected with RSV
may induce the transendothelial migration of human
blood eosinophils by RANTES.53
Interleukin-8 is a major neutrophil chemoattractant54
and may play an important role in asthma exacerba-
tion.55,56 It can also act as a chemoattractant for
eosinophils primed by IL-3, IL-5 or GM-CSF.57 Interleukin-
11 is a new pleiotropic cytokine of the IL-6 family. It is
known to be a T cell-dependent stimulator of B cell
immunoglobulin production and can induce airway
hypersensitivity and bronchospasms caused by choliner-
gic effects and tachykinin production.58 A recent study
has shown an increase in IL-11 concentrations in
nasopharyngeal aspirates from children with upper
respiratory infections.59 The GM-CSF also has the ability
to activate eosinophils. The roles of pro-inflammatory
cytokines, such as IL-1b , IL-6, IFN- g and TNF-a, in
eosinophil infiltration are not clear. These results suggest
that some cytokines and chemokines generated from
infected airway epithelial cells seem to contribute to
eosinophil infiltration.
Respiratory syncytial virus antigen
A massive infiltration of eosinophils has been found in the
postmortem lungs of RSV-infected children who had
received FI-RSV vaccine and recipients of this vaccine
had peripheral eosinophilia at the time of subsequent
natural RSV infection.30
The mechanisms of eosinophilia that has been induced
by the RSV vaccine have been clarified with studies using
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Fig. 2 Counterinhibitory link
between T helper cell subsets. T
helper (Th)1 cells are typical
antiviral immune effectors and
are central to the coordination
of the classic immune responses
to antigens presented by
macrophages and dendritic 
cells. The Th2 cells appear to 
be specialized for allergic
responses in the asthmatic
airway. IFN-g , interferon-g ; GM-
CSF, granulocyte–macrophage
colony stimulating factor; IL,
interleukin; TNF, tumor necrosis
factor. Reproduced with per-
mission from Openshaw and
O’Donnell.41
mice. BALB/c mice inoculated with the FI-RSV vaccine
developed a Th2-like pattern of cytokines in the lungs
when later challenged with RSV intranasally. In contrast,
inoculation with live RSV induced a Th1-like pattern of
cytokines.60 Following immunization with recombinant
vaccinia viruses (rVV) expressing individual RSV proteins
G and F, clear results were obtained in studies of BALB/c
mice sensitized with rVV and challenged 5 days later with
live RSV intranasally. Mice sensitized with G-protein pro-
duced high levels of IL-4 and -5 in the lung and
developed extensive pulmonary eosinophilia, while mice
sensitized with F protein produced IL-2 and developed
mononuclear cell infiltration.61 These results indicate that
the G-protein can strongly induce a Th2-like response.
Further experiments have shown similar results in mice
sensitized with individual RSV proteins (Table 3).62,63
A recent study has shown that mice treated with IL-12
at various times during immunization by G-protein
vaccine and challenged by RSV had reduced vaccine-
induced lung eosinophilia but increased total pulmonary
lymphocyte infiltration. Cytokine analysis showed that
IFN-g production increased, whereas IL-4 and -5 produc-
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Fig. 3 Summary of the effects of viruses of the upper respiratory tract that may lead to exacerbations of asthma. Viruses (center)
have been shown to induce epithelial disruptions, cholinergic and adrenergic nerve dysfunctions and inactivations of tachykinins,
such as substance P (SP). These have resulted in the development of neurogenic inflammation. Viruses have also been shown to
interact with airway epithelium leading to increases in the production of interleukin (IL)-6, IL-8, IL-11, granulocyte–macrophage
colony stimulating factor (GM-CSF) and the chemokines macrophage inflammatory protein (MIP)-1 and regulated upon activation,
normal T cell expressed and presumably secreted (RANTES). These induce B and T cell up-regulation and an increased number of
eosinophils and neutrophils. This interaction may also lead to increases in nitric oxide (NO) that may inhibit Th1 proliferation.
Viruses may act on CD8+ T lymphocytes to cause a shift to a T helper cell (Th) 2-type pattern of cytokine production. They have also
been shown to act on monocytes and macrophages, leading to increased production of interferon (IFN)-b , IL-1 b , IL-6 and tumor
necrosis factor (TNF)-a , and on basophils, leading to increases in basophil histamine releasability and leukotriene (LT)C4 production.
All these factors may contribute to the development of exacerbations of asthma following upper respiratory tract infection.
Reproduced with permission from Corne and Holgate.43
tion decreased,64 suggesting that IL-12 may be the key
cytokine of the Th1 response by producing IFN-g , which
controls the Th2 response in viral infection.65
EOSINOPHIL INFILTRATION AND BRONCHIOLITIS
Children with RSV infection have been shown to develop
an RSV-specific IgE response in the airway.66 The concen-
trations of RSV IgE in wheezy infants are higher than those
in children who do not wheeze after RSV infection.67 The
degree of RSV IgE responsiveness was correlated with the
severity of illness by the degree of hypoxia. In addition,
the RSV IgE response was correlated with increased con-
centrations of histamine in the nasopharyngeal aspirates
of infants with bronchiolitis.68 Leukotriene (LT)C4, which is
a potent bronchoconstrictor metabolite of the arachi-
donic acid cascade in eosinophils, has been detected in
the nasopharyngeal aspirates of infants with RSV infec-
tion. The concentrations of LTC4 detected were correlated
with those of the RSV IgE.69 Leukotriene E4, a selective
eosinophil chemotactic factor, was present in the respira-
tory tract of infants with RSV bronchiolitis. Concentrations
of LTB4, a chemoattractant of inflammatory cells, were
significantly correlated with the degree of hypoxia,
although LTB4 has little bronchoconstrictor activity. It 
has been suggested that LTB4 levels may reflect the acti-
vation of inflammatory cells, such as neutrophils and
eosinophils, in the airway.70
Significant increases in the levels of eosinophil cationic
protein, an indicator of the activity of eosinophils, were
observed in nasopharyngeal aspirates from infants with
RSV bronchiolitis and from asthmatic school-age chil-
dren.71–73 These findings suggest that eosinophil
activation occurs in the respiratory tract during RSV bron-
chiolitis and may play a significant role in the
development of virus-induced airway obstruction. With
regard to the mechanism of eosinophilia in the airway in
bronchiolitis, we have demonstrated that the Th2-type
cytokines IL-4 and IL-5 were not detected, whereas the
Th1-type cytokines IFN-g and IL-12 and the chemokines
RANTES and IL-8 were detectable in nasopharyngeal
aspirates.74,75 These results suggest that chemokines from
epithelial cells may induce eosinophil infiltration in the
airway in RSV bronchiolitis, as in asthma.
SUMMARY
A number of causes have been postulated for the
increased airway reactivity of asthma. Well-controlled
investigations have demonstrated that respiratory viruses
are major etiologic factors. In infants, the most important
infectious agent is RSV. The mechanism by which RSV
induces asthma-like symptoms is unknown, but it is prob-
able that the resulting inflammatory changes in the
airway mucosa alter host defenses and make the airway
more susceptible to exogenous stimuli. Because a strong
link between bronchiolitis and later asthmatic symptoms
has been indicated from many studies, it is crucial to 
elucidate the association between viral infection and
asthma. Findings will be useful for the prevention of RSV
bronchiolitis, which will result in the prevention of asthma
development in sensitive individuals.
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